Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: A phase III randomized, multicenter, clinical trial

Oncology

Volumn 78, Issue 1, 2010, Pages 54-61

  Kulig, J ^a   Kolodziejczyk, P ^a   Sierzega, M ^a   Bobrzynski, L ^a   Jedrys, J ^a   Popiela, T ^a   Dadan, J ^b   Drews, M ^c   Jeziorski, A ^d   Krawczyk, M ^e   Starzynska, T ^f   Wallner, G ^g  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

^f POMERANIAN MEDICAL UNIVERSITY   (Poland)

^g MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Adjuvant chemotherapy; Cisplatin; Doxorubicin; Etoposide; Etoposide Adriamycin cisplatin regimen; Gastric cancer

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; FEMALE; FEVER; GASTRECTOMY; HEART ARREST; HEART DISEASE; HUMAN; INFECTION; INJECTION SITE REACTION; KIDNEY DISEASE; LEUKOPENIA; LIVER DISEASE; LUNG DISEASE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PATIENT CARE; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEROSA; SKIN DISEASE; STOMACH CANCER; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FEMALE; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 77649307415     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000292360     Document Type: Article

References (24)

1. Clark CJ, Thirlby RC, Picozzi V Jr, Schembre DB, Cummings FP, Lin E: Current problems in surgery: gastric cancer. Curr Probl Surg 2006; 43: 566-670.
2. Wolfrum F, Vogel I, Fandrich F, Kalthoff H: Detection and clinical implications of minimal residual disease in gastro-intestinal cancer. Langenbecks Arch Surg 2005; 390: 430-441.
3. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, Van de Velde CJ: Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993; 11: 1441-1447.
4. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, Cascinu S, Barni S, Labianca R, Torri V: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000; 11: 837-843.
5. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a metaanalysis of randomised trials. Eur J Cancer 1999; 35: 1059-1064.
6. Panzini I, Gianni L, Fattori PP, Tassinari D, Imola M, Fabbri P, Arcangeli V, Drudi G, Canuti D, Fochessati F, Ravaioli A: Adjuvant chemotherapy in gastric cancer: a metaanalysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002; 88: 21-27.
7. Carrato A, Gallego-Plazas J, Guillen-Ponce C: Adjuvant therapy of resected gastric cancer is necessary. Semin Oncol 2005; 32:S105-S108.
8. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J, Meyer HJ, Buente H: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989; 7: 1310-1317.
9. Wilke H, Preusser P, Fink U, Gunzer U, Meyer HJ, Meyer J, Siewert JR, Achterrath W, Lenaz L, Knipp H, et al: Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989; 7: 1318-1326.
10. Haim N, Tsalik M, Robinson E: Treatment of gastric adenocarcinoma with the combination of etoposide, Adriamycin and cisplatin (EAP): comparison between two schedules. Oncology 1994; 51: 102-107.
11. Taal BG, ten Bokkel Huinink WW, Franklin H, Rodenhuis S: EAP in advanced gastric cancer. J Clin Oncol 1990; 8: 939-941.
12. Sparano JA, Wiernik PH: Toxicity of etoposide, doxorubicin, and cisplatin in gastric cancer. J Clin Oncol 1990; 8: 938-939.
13. Sobin L, Wittekind C: TNM Classification of Malignant Tumors: International Union against Cancer. New York, Wiley, 2002.
14. Forman D, Burley VJ: Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 2006; 20: 633-649.
15. Preusser P, Wilke H, Achterrath W, Neuhaus B, Balleisen L, Meyer J, Van de Loo J: Advanced inoperable stomach cancer: a pilot study with the combination etoposide, Adriamycin and cisplatin. Anticancer Res 1986; 6: 1195-1196.
16. Bajetta E, Buzzoni R, Mariani L, Beretta E, Bozzetti F, Bordogna G, Aitini E, Fava S, Schieppati G, Pinotti G, Visini M, Ianniello G, Di BM: Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 2002; 13: 299-307.
17. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820.
18. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
19. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
20. Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T: Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol 2002; 9: 278-286.
21. Kurokawa Y, Sasako M: Recent advances in chemotherapy and chemoradiotherapy for gastrointestinal tract cancers: adjuvant chemoradiotherapy for gastric cancer. Int J Clin Oncol 2008; 13: 479-482.
22. Kozak KR, Moody JS: The survival impact of the intergroup 0116 trial on patients with gastric cancer. Int J Radiat Oncol Biol Phys 2008; 72: 517-521.
23. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, Sasako M, Kunii Y, Motohashi H, Yamamoto S: Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 2003; 21: 2282-2287.
24. Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K, Goto M: Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosanegative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet 1999; 354: 273-277.